Search results
2 Biotech Stocks to Buy in May
Motley Fool via Yahoo Finance· 5 hours agoIts next-gen CF therapy also aced a late-stage study, and it advanced inaxaplin, an investigational treatment for APOL-1 mediated kidney disease, to the...
Certain menopausal hormone therapy could raise ovarian cancer risk, study finds
BioPharma Dive via Yahoo Finance· 2 days ago“Our study provides the only long-term information from a randomized clinical trial on two common...
Does Medicare Part D cover prescriptions for clinical trials? | Chattanooga Times Free Press
Chattanooga Times Free Press· 2 hours agoAre clinical trial prescriptions covered under Medicare's drug plans? What a smart decision you made...
Cancer Clinical Trial Participation May Not Actually Improve Survival, Study Says
MedPage Today· 4 days agoCancer clinical trial participation was not associated with longer survival after accounting for...
Ozempic maker sets clinical trial to study drug's effect on alcohol consumption
Scripps News via AOL· 5 days agoAnd while Danish drugmaker Novo Nordisk has acknowledged that possibility, it's not precisely the...
Study finds good clinical outcomes for over 30% of ischemic stroke patients receiving endovascular...
Medical Xpress· 5 days agoThe study, conducted over five years, found that over 30% of patients who received endovascular treatment had a good clinical outcome even after six hours ...
Seastar touts positive case studies for selective cytopheretic device
Medical Device Network via Yahoo Finance· 1 day agoThe estimated completion date of the study is in 2025. In February 2024, Seastar received FDA...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...
WTNH-TV New Haven· 8 hours agoIn the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS)...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing ...
FOX21 Colorado Springs· 9 hours agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical< ...
Study finds many GLP-1 weight-loss patients discontinue treatment too soon
theGrio· 3 days agoPatients begin with a low dose of the medications and are supposed to gradually increase it over...
